Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity

Abstract

Purpose

Severe hepatotoxicity induced by the standard dose of gefitinib (250 mg daily) often becomes manageable by dose reduction to 250 mg every other day. Thus, we hypothesized that systemic exposure of standard-dose gefitinib in patients with experience of severe hepatotoxicity might be higher than that in patients without severe hepatotoxicity.

Methods

Patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer who were receiving gefitinib either at a reduced dose (250 mg every other day) because of intolerable severe toxicity or at a standard dose (250 mg daily) were enrolled. A series of blood samples were collected to estimate pharmacokinetic parameters and calculate systemic exposure of standard-dose gefitinib (area under the concentration–time curve from 0 to 24 h at steady state, AUC0–24,ss). Systemic exposure of unbound gefitinib (fu·AUC0–24,ss) was also assessed, because gefitinib is extensively bound to serum proteins.

Results

Of the 38 enrolled patients, 34 (23 patients without experience of severe hepatotoxicity, 11 patients with experience of severe hepatotoxicity) were evaluable. There was no significant differences in total AUC0–24,ss or unbound fu·AUC0–24,ss between patients with and without experience of severe hepatotoxicity. Analysis of the time to severe hepatotoxicity indicated no difference between patients with a high AUC0–24,ss and those with a low AUC0–24,ss of either total or unbound gefitinib.

Conclusion

This study suggests that reversible severe hepatotoxicity is not caused by high systemic exposure of gefitinib.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29. https://doi.org/10.3322/caac.20138

  2. 2.

    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388

  3. 3.

    Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. https://doi.org/10.1016/S1470-2045(09)70364-X

  4. 4.

    Satoh H, Inoue A, Kobayashi K, Maemondo M, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T (2011) Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6(8):1413–1417. https://doi.org/10.1097/JTO.0b013e31821d43a8

  5. 5.

    Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21(12):2237–2246. https://doi.org/10.1200/JCO.2003.10.038

  6. 6.

    Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20(9):2240–2250. https://doi.org/10.1200/JCO.2002.10.112

  7. 7.

    Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14(6):922–930. https://doi.org/10.1093/annonc/mdg250

  8. 8.

    Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24(4):291–297. https://doi.org/10.1007/s10637-006-5269-2

  9. 9.

    Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K, Molimard M (2011) Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 412(11–12):1060–1067. https://doi.org/10.1016/j.cca.2011.02.023

  10. 10.

    Validation. Rockville, Food and Drug Administration (2001) Guidance for Industry: Bioanalytical Method US Department of Health and Human Services. FDA, Center for Drug Evaluation and Research

  11. 11.

    Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, Spriet I (2014) Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci 103(8):2565–2570. https://doi.org/10.1002/jps.24064

  12. 12.

    NCI, Common Terminology Criteria for Adverse Events Version 4.0. NCI, NIH, DHHS. 2009. Available at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 29 May 2009

  13. 13.

    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

  14. 14.

    Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40(1):1–47

  15. 15.

    Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98(10):1633–1640. https://doi.org/10.1038/sj.bjc.6604355

  16. 16.

    Kenmotsu H, Imamura CK, Ono A, Omori S, Nakashima K, Wakuda K, Taira T, Naito T, Murakami H, Takahashi T, Tanigawara Y (2017) The effects of advanced age and serum alpha1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. Br J Clin Pharmacol 83(11):2416–2425. https://doi.org/10.1111/bcp.13354

  17. 17.

    Kawata T, Higashimori M, Itoh Y, Tomkinson H, Johnson MG, Tang W, Nyberg F, Jiang H, Tanigawara Y (2019) Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-019-03788-4

  18. 18.

    Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, Baker SD (2006) CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98(23):1714–1723. https://doi.org/10.1093/jnci/djj466

  19. 19.

    Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98(23):1739–1742. https://doi.org/10.1093/jnci/djj469

  20. 20.

    Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR (2011) HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29(6):667–673. https://doi.org/10.1200/JCO.2010.31.3197

  21. 21.

    Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN (2016) HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clin Cancer Res 22(6):1371–1377. https://doi.org/10.1158/1078-0432.CCR-15-2044

  22. 22.

    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. https://doi.org/10.1056/NEJMoa040938

  23. 23.

    Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149–2158. https://doi.org/10.1001/jama.290.16.2149

Download references

Acknowledgements

This work was supported by JSPS KAKENHI Grant Number JP16K09568. We thank all the patients who participated in this study and their families. We also thank Ms. Mie Yamada, Ms. Chiemi Asano, and Ms. Miho Watanabe (Division of Thoracic Oncology, Shizuoka Cancer Center) for study management; Ms. Yumiko Iwamoto, Ms. Yumi Oguma, Ms. Masayo Kaneko, Ms. Satomi Koizumi, and Ms. Yukako Kawano (Nursing Department, Shizuoka Cancer Center) for blood sampling; and Dr. Haruki Kobayashi, Dr. Norimitsu Kasahara, Dr. Takumi Fujiwara, Dr. Mie Kotake, and Dr. Nobuaki Mamesaya (Division of Thoracic Oncology, Shizuoka Cancer Center) for their contributions to this study.

Author information

Correspondence to Yusuke Tanigawara.

Ethics declarations

Conflict of interest

Chiyo K. Imamura, Hirotsugu Kenmotsu, Shota Omori, Kazushige Wakuda, Haruyasu Murakami, Toshiaki Takahashi, and Yusuke Tanigawara have received honouraria from AstraZeneca. Kazushige Wakuda, Hirotsugu Kenmotsu, and Toshiaki Takahashi have received a grant from AstraZeneca. For the remaining authors, no conflicts of interest are declared. All of the conflicts of interest are outside the submitted work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kawamura, T., Imamura, C.K., Kenmotsu, H. et al. Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. Cancer Chemother Pharmacol 85, 605–614 (2020). https://doi.org/10.1007/s00280-020-04034-y

Download citation

Keywords

  • Gefitinib
  • Non-small cell lung cancer
  • Pharmacokinetics
  • Protein binding
  • Severe hepatotoxicity
  • Systemic exposure